Maryam Nazari

Maryam Nazari

Auto-generated profile, based on publicly available information

Maryam Nazari

Food Safety Research Center (salt), Semnan University of Medical Sciences, Semnan, Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2011 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
AGAsghar Ghorbani
Asghar Ghorbani
MNMaryam Nazari
Maryam Nazari
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
HZHamid Zand
Hamid Zand

Verified
Journal Article
Open access
PDF file
Mahsa JaliliMahsa Jalili
Mahsa Jalili
MNMaryam Nazari
Maryam Nazari
FMFaidon Magkos
Faidon Magkos
Fermented foods are part of the staple diet in many different countries and populations and contain various probiotic microorganisms and non-digestible prebiotics. Fermentation is the process of breaking down sugars by bacteria and yeast species; it not only enhances food preservation but can also increase the number of beneficial gut bacteria. Regular consumption of fermented foods has been associated with a variety of health benefits (although some health risks also exist), including improved digestion, enhanced immunity, and greater weight loss, suggesting that fermented foods have the potential to help in the design of effective nutritional therapeutic approaches for obesity. In this article, we provide a comprehensive overview of the health effects of fermented foods and the corresponding mechanisms of action in obesity and obesity-related metabolic abnormalities.

1 January 2011 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MNMaryam Nazari
Maryam Nazari
AGAsghar Ghorbani
Asghar Ghorbani
AHAzita Hekmat-Doost
Azita Hekmat-Doost
MJMahmood Jeddi-Tehrani
Mahmood Jeddi-Tehrani
HZHamid Zand
Hamid Zand

1 February 2012 in Nutrition
Verified
Journal Article
Closed access
HSHadis Sabour
Hadis Sabour
AJAbbas Noroozi Javidan
Abbas Noroozi Javidan
MVMohammadreza Vafa
Mohammadreza Vafa
FSFarzad Shidfar
Farzad Shidfar
MNMaryam Nazari
Maryam Nazari
HRHasan Emami Razavi
Hasan Emami Razavi

15 January 2016 in Oman Medical Journal
Verified
Journal Article
Open access
HSHadis Sabour
Hadis Sabour
MNMaryam Nazari
Maryam Nazari
SLSahar Latifi
Sahar Latifi
ZSZahra Soltani
Zahra Soltani
HSHania Shakeri
Hania Shakeri
SRSeyed-Hassan Emami Razavi
Seyed-Hassan Emami Razavi
The effect of dietary protein intake on bone mineral density (BMD) has not been explained in patients with spinal cord injury (SCI). In this study, we looked at the relationship between BMD and higher protein intake in patients with SCI while controlling for possible confounders. Patients with SCI, who were referred to the Brain and Spinal Cord Injury Research Center between November 2010 and April 2012, were included in the study. In total, the dietary intakes of 103 patients were assessed by 24-hour dietary recall interviews. We used dual-energy X-ray absorptiometry to measure BMD in the femoral neck, trochanter, intertrochanteric zone, hip, and lumbar vertebras. Eighty-six men and 17 women participated in this study. Protein intake was negatively associated with the BMD of lumbar vertebrae (p = 0.001, r = -0.37 for T-score and p = 0.030, r = -0.24 for Z-score). The BMD of lumbar vertebrae were negatively associated with intake of tryptophan, isoleucine, lysine, cysteine, and tyrosine (p = 0.007, 0.005, 0.009, 0.008, and 0.008 for T-score, respectively). Higher intakes of threonine, leucine, methionine, phenylalanine, valine, and histidine were related to a lower BMD of lumbar vertebrae (p = 0.006, 0.010, 0.009, 0.010, 0.009, and 0.008 respectively for T-scores). We found that high protein intake led to a lower BMD of lumbar vertebrae in patients with SCI after controlling for confounders including demographic and injury-related characteristics and calcium intake. No relationship between higher amino acids intake and BMD of the femur and hip was detected. Intake of alanine, arginine, and aspartic acid were not related to BMD.

1 April 2018 in Journal of Cancer Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
RSRoghayeh Shahbazi
Roghayeh Shahbazi
MCMakan Cheraghpour
Makan Cheraghpour
RHReza Homayounfar
Reza Homayounfar
MNMaryam Nazari
Maryam Nazari
JNJavad Nasrollahzadeh
Javad Nasrollahzadeh
SDSayed Hossein Davoodi
Sayed Hossein Davoodi
Context: It has been shown that hesperidin induces apoptosis in NALM-6 cells through inhibition of nuclear factor-kappa B (NF-κB) activation. Aims: To investigate the effect of hesperidin on inhibition of NF-κB activation through blocking phosphoinositide 3–kinase (PI3K)/Akt pathway as a main target in cancer treatment, in NALM-6 cells. Materials and Methods: NALM-6 cells were incubated with two concentrations of hesperidin (25, 50 μM) in the presence or absence of insulin (100 nM), as a potent activator of Akt. The cytotoxic activity of hesperidin was determined by 3-(4,5-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell apoptotic death was measured by ELISA test using cell death detection ELISA Plus kit. To assay the effect of hesperidin on Akt pathway, the phosphorylation levels of Akt, inhibitor of kappa B alpha (IκBα), and glycogen synthase kinase-3 beta (GSK-3β) and expression level of IκB kinase alpha (IKKα) were determined by Western blot analysis. Results: Hesperidin (both concentrations) significantly reduced cells survival in the presence and absence of insulin compared to untreated cells in a time-dependent manner ( P < 0.05). Hesperidin also significantly increased apoptosis in NALM-6 cells even in hyperinsulinemia condition ( P < 0.0001). Hesperidin inhibited insulin-induced phosphorylation and activation of Akt, IκBα, and GSK-3β and decreased expression of IKKα. Conclusion: The results of this study demonstrated that cytotoxic and proapoptotic actions of hesperidin are partly mediated through the suppression of PI3K3/Akt/IKK signaling pathway. So, hesperidin might act as a chemotherapeutic agent by targeting cell survival pathways.